Blog

Big Thank You to Blue Gallery!
February 22, 2020
Big Thank You to Blue Gallery!

A million thank you’s to Steve Dupler who owns the fabulous Blue Gallery! He opened the doors to ASPIRE so we could begin work on an advocacy project. Blue Gallery is a gem of a NYC venue and...

Read More

Category:  Blog
Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection

Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection

Brian A.Fallon, BarbaraStrobino, SeanReim, JulieStoner, Madeleine W.Cunningham Brain, Behavior, & Immunity – Health, Volume 2, February 2020, 100015. https://doi.org/10.1016/j.bbih.2019.100015

This study examines molecular mimicry targeting neural tissue after Borrelia burgdorferi (Bb) infection. Patients with Lyme disease have a greater frequency of specific anti-neuronal autoantibodies and functional neuronal activation compared to community controls without a history of Lyme disease.

“Highlights

  • The EM ​+ ​prior LD group had significantly elevated anti-neuronal antibodies.
  • The EM ​+ ​prior LD group had significantly elevated CaM Kinase activation.
  • Anti-Lysoganglioside Antibodies are significantly elevated in the PTLS group.
  • Prior infection may lead to immune priming and increased autoantibodies.”
A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder
Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019 Dec;282:112602. doi: 10.1016/j.psychres.2019.112602. Epub 2019 Oct 4. PMID: 31630042.
  • Objective: Evaluate the efficacy of memantine as a glutamate modulator for moderate to severe OCD.
  • Methods: Systematic review of single, double-blinded, and open-label trials, using Y-BOCS scores as the primary measure.
  • Results:
    • 8 studies, 125 participants receiving memantine augmentation.
    • Significant reduction of 11.73 points in Y-BOCS scores.
    • Patients on memantine were 3.61 times more likely to respond than those on placebo.
    • 20 mg/day memantine for at least 8 weeks is safe and effective.
  • Conclusions: Memantine augmentation is a promising treatment option for moderate to severe OCD.